CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gelteq Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gelteq Ltd
Level 4, 100 Albert Road
Phone: +61 390873990p:+61 390873990 MELBOURNE, VIC  3205  Australia
Business Summary
Gelteq Ltd is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. It offers proprietary and patented Gel Science technology in oral drug and nutrient delivery. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. Its technology allows to create gels from a range of existing products and ingredients into an edible gel, including carbohydrates, proteins, fats, vitamins, nutraceuticals, or medicinal components. The Company's delivery system is designed for pharmaceutical, nutraceutical, pet care, and sports use. The gels are customized to suit different flavor profiles and allow for effective taste masking of unpleasant ingredients.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20226/30/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Simon H.Szewach 43 8/1/2021 8/1/2021
Chief Executive Officer, Executive Director Nathan J.Givoni 39
Chief Financial Officer Craig J.Young 59 2/1/2023 2/1/2023
Independent Non-Executive Director Philip A.Dalidakis 47 4/12/2022 4/12/2022
Independent Non-Executive Director Jeffrey W.Olyniec 49 8/5/2021 8/5/2021

General Information
Outstanding Shares: 9,560,303 (As of 8/30/2022)


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024